Laura Johnson
About Laura Johnson
Laura Johnson, 43, is Vice President of Operations at Inspire Veterinary Partners (IVP) since September 2024. She brings 16+ years of veterinary services leadership across multi-site operations, with prior oversight of a $200M revenue portfolio spanning 150+ practices at Western Veterinary Partners and regional profit/accountability at National Veterinary Associates; education includes the Franklin College of Arts and Sciences at the University of Georgia and ongoing studies in applied business/technology at Arizona State University . Her operating track record emphasizes scaling, profitability improvement, and team-building across large practice networks, including managing $60M+ regions and hospitals representing $18M in annual revenue .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Inspire Veterinary Partners (IVP) | Vice President of Operations | Sep 2024 – Present | Leads operations for IVP; appointed VP Ops with mandate to improve profitability and multi-site execution . |
| Western Veterinary Partners | Vice President of Operations | Apr 2023 – Aug 2024 | Oversaw ~$200M revenue across 150+ veterinary practices in the Western U.S., driving multi-site operational performance . |
| Western Veterinary Partners | Senior Director of Operations | Jan 2023 – Apr 2023 | Directed $60–$90M revenue portfolio; oversight of up to ~60 practices, scaling operational controls . |
| Western Veterinary Partners | Director of Operations | Oct 2021 – Jan 2023 | Led $60–$90M revenue portfolios; multi-site leadership and profitability initiatives . |
| National Veterinary Associates | Manager of Regional Operations | Feb 2019 – Oct 2021 | Responsible for 22 practices in UT/NV generating >$60M annually; delivered regional profit/accountability . |
| National Veterinary Associates | Associate Manager, Regional Operations | Oct 2018 – Feb 2019 | Managed six hospitals representing >$18M annual revenue; operational execution and growth . |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Nationally accredited e-commerce veterinary pharmacy (family-founded) | Co-founder/Operator | First eight years of career | Licensed in all 50 states; Vet‑VIPPS and PCAB accredited; led launch, scale, marketing strategy and execution . |
Equity Ownership & Alignment
- IVP has not adopted a policy prohibiting directors/officers/employees from hedging or short-term/speculative transactions (e.g., short sales, options), nor from pledging/margin use of company stock—an alignment risk if executives hedge/pledge positions .
- Beneficial ownership is disclosed for named executive officers and directors; Laura Johnson is not listed individually, and her beneficial holdings are not broken out in the latest proxy (executive group totals are presented without a Johnson line item) .
Employment Terms
- No individual employment agreement, severance, change‑of‑control, or incentive plan disclosure for Laura Johnson in IVP’s proxy (company presents “smaller reporting company” executive compensation focused on named executive officers) .
- Compensation oversight resides with IVP’s independent Compensation Committee (Chair: Anne Murphy), which reviews/approves executive pay and equity plans; committee met four times in 2024 .
- IVP adopted an Executive Incentive Compensation Recovery (clawback) policy per SEC Rule 10D‑1/Nasdaq Listing Rule 5608, enabling recovery of erroneously awarded incentive compensation in restatement scenarios .
Investment Implications
- Strong operator: Johnson’s prior leadership over ~$200M revenue and 150+ practices suggests capability to drive IVP’s multi-site performance and margin discipline—potentially supportive for revenue growth and EBITDA stabilization if execution translates to IVP’s footprint .
- Data gaps: Absence of disclosed Johnson-specific pay mix, performance metrics, vesting schedules, ownership, and severance/CoC terms limits pay‑for‑performance assessment and retention risk modeling at IVP; investors must monitor future proxies and 8‑Ks for executive-specific filings .
- Governance alignment risks: Lack of hedging/pledging prohibitions introduces potential misalignment/overhang if insiders hedge or pledge shares; the clawback policy partially mitigates restatement-related incentive risk .
- Context: Named executive officers had no outstanding equity awards at year‑end 2024, and director options were fully vested on grant—signals to watch for evolution of equity program design and retention incentives affecting senior operators like Johnson .